Theriva™ biologics reports first quarter 2024 operational highlights and financial results

- reported topline data from the investigator sponsored phase 1 trial of intravitreal vcn-01 in pediatric patients with refractory retinoblastoma; trial results were determined to be positive by the study monitoring committee-
TOVX Ratings Summary
TOVX Quant Ranking